Four Weeks of Preoperative Omega-3 Fatty Acids Reduce Liver Volume: a Randomised Controlled Trial

Obes Surg. 2019 Jul;29(7):2037-2044. doi: 10.1007/s11695-019-03814-7.

Abstract

Purpose: Weight loss before bariatric surgery with a low-calorie diet (LCD) has several advantages, including reduction of liver volume and an improved access to the lesser sac. Disadvantages include performing surgery in a state of undernutrition, side effects, costs and patient compliance. Omega-3 fatty acids may serve as an alternative to reduce liver steatosis.

Materials and methods: A randomised controlled open-label trial was done to compare the effects of a LCD with Modifast (800 kcal/day) during 2 weeks with 2 g of omega-3 fatty acids a day and a normal diet (2000 kcal/day) during 4 weeks. Total liver volume (TLV) and volume of the left liver lobe (LLL), visceral fat area (VFA) and muscle area (SMA) at the L3-L4 level were measured with MRI before and after preoperative treatment.

Results: Sixty-two morbidly obese women undergoing laparoscopic Roux-en-Y gastric bypass surgery (LRYGB) were recruited. In both groups, there was a significant decrease in LLL, TLV and VFA. For LLL and TLV reduction, the LCD had a significantly larger effect (p < 0.05). Only in the LCD group was there a significant decrease in SMA with significantly more side effects and worse compliance.

Conclusion: Both the LCD and omega-3 diet reduced LLL, TLV and VFA. The LCD outperformed the omega-3 diet in LLL and TLV reduction, but induced significant loss of SMA and had worse compliance due to more side effects. Omega-3 fatty acids may provide a safe and more patient-friendly alternative for a LCD and further research is indicated.

Trial registration: The study is registered at www.clinicaltrials.gov (NCT02206256).

Keywords: Laparoscopic Roux-en-Y gastric bypass; Liver volume; Low calorie diet; Muscle mass; Omega-3 fatty acids; Visceral fat.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Body Composition / drug effects
  • Body Composition / physiology
  • Caloric Restriction / methods*
  • Combined Modality Therapy
  • Dietary Fats, Unsaturated / administration & dosage
  • Dietary Fats, Unsaturated / pharmacology
  • Dietary Supplements
  • Fatty Acids, Omega-3 / administration & dosage*
  • Fatty Acids, Omega-3 / pharmacology
  • Fatty Liver / complications
  • Fatty Liver / diagnosis
  • Fatty Liver / diet therapy
  • Fatty Liver / surgery
  • Female
  • Gastric Bypass / methods
  • Humans
  • Intra-Abdominal Fat / diagnostic imaging
  • Intra-Abdominal Fat / drug effects
  • Intra-Abdominal Fat / pathology
  • Laparoscopy
  • Liver / diagnostic imaging
  • Liver / drug effects
  • Liver / pathology*
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Obesity, Morbid / complications
  • Obesity, Morbid / diagnosis
  • Obesity, Morbid / diet therapy*
  • Obesity, Morbid / surgery*
  • Organ Size / drug effects
  • Preoperative Care / methods*
  • Weight Loss / physiology
  • Young Adult

Substances

  • Dietary Fats, Unsaturated
  • Fatty Acids, Omega-3

Associated data

  • ClinicalTrials.gov/NCT02206256